

Laura Bonanno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/104633/publications.pdf>

Version: 2024-02-01

68
papers

1,884
citations

304743

22
h-index

289244

40
g-index

72
all docs

72
docs citations

72
times ranked

3240
citing authors

#	ARTICLE	IF	CITATIONS
1	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , 2022, 27, 87-e115.	3.7	25
2	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296.	7.0	14
3	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	3
4	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , 2022, 127, 383-393.	6.4	36
5	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 202-220.	2.8	29
6	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103378.	4.4	12
7	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021, 17, 2513-2527.	2.4	7
8	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3.	2.6	19
9	ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). <i>Clinical Lung Cancer</i> , 2020, 21, 15-20.	2.6	58
10	Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 66.	4.1	12
11	Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 564915.	2.8	7
12	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1810-1821.	2.8	7
13	Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 123, 81-91.	6.4	35
14	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. <i>Oncologist</i> , 2020, 25, e1996-e2005.	3.7	21
15	Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1601.	4.1	7
16	Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 607840.	2.8	10
17	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , 2020, 87, 102031.	7.7	82
18	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	3.7	6

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. , 2019, 7, 205.		72
20	Editorial on “The AvaALL Randomized Clinical Trial” Journal of Thoracic Disease, 2019, 11, S1237-S1240.	1.4	1
21	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. Lung Cancer, 2019, 134, 121-126.	2.0	4
22	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	7.0	139
23	Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections?. World Journal of Surgery, 2019, 43, 1385-1392.	1.6	10
24	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. Lung Cancer, 2019, 133, 62-68.	2.0	5
25	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 1874.	4.1	39
26	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. Critical Reviews in Oncology/Hematology, 2019, 138, 87-103.	4.4	16
27	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Oncologist, 2019, 24, 1128-1136.	3.7	156
28	18F-FDG PET/CT in non-small-cell lung cancer patients. Nuclear Medicine Communications, 2019, 40, 802-807.	1.1	63
29	Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy. Journal of Thoracic Oncology, 2019, 14, e5-e7.	1.1	7
30	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clinical Lung Cancer, 2019, 20, e186-e194.	2.6	40
31	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist, 2019, 24, e318-e326.	3.7	5
32	Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases. Translational Lung Cancer Research, 2019, 8, S435-S438.	2.8	2
33	Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. PeerJ, 2019, 7, e7232.	2.0	27
34	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.. Journal of Clinical Oncology, 2019, 37, e20612-e20612.	1.6	0
35	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Future Oncology, 2018, 14, 353-361.	2.4	3
36	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876374.	3.2	30

#	ARTICLE	IF	CITATIONS
37	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2585-2592.	1.6	42
38	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 19-29.	4.4	14
39	The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. <i>European Journal of Cancer</i> , 2018, 101, 191-200.	2.8	86
40	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1021-1030.	2.4	21
41	ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8587-TPS8587.	1.6	4
42	IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKC α 1 inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e24001-e24001.	1.6	0
43	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24074-e24074.	1.6	0
44	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. <i>Clinical Cancer Research</i> , 2017, 23, 3316-3324.	7.0	43
45	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. <i>Lung Cancer</i> , 2017, 108, 15-21.	2.0	10
46	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 30-39.	4.4	40
47	Efficacy of the addition of cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicenter, randomized phase III MILES-3 and MILES-4 studies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9002-9002.	1.6	5
48	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017, 8, 32626-32638.	1.8	14
49	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. <i>OncoTargets and Therapy</i> , 2016, 9, 3671.	2.0	3
50	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 312.	2.6	21
51	166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series. <i>Journal of Thoracic Oncology</i> , 2016, 11, S130.	1.1	0
52	28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS). <i>Journal of Thoracic Oncology</i> , 2016, 11, S67.	1.1	0
53	77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC). <i>Journal of Thoracic Oncology</i> , 2016, 11, S88.	1.1	1
54	Unusual echocardiographic appearance of a cardiac metastasis from lung carcinoma. <i>Journal of Clinical Ultrasound</i> , 2016, 44, 392-394.	0.8	2

#	ARTICLE	IF	CITATIONS
55	211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis. <i>Journal of Thoracic Oncology</i> , 2016, 11, S148.	1.1	1
56	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. <i>Lung Cancer</i> , 2016, 96, 52-55.	2.0	8
57	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016, 7, 25050-25063.	1.8	6
58	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. <i>American Journal of Case Reports</i> , 2015, 16, 782-789.	0.8	10
59	Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. <i>Cancer Biology and Therapy</i> , 2015, 16, 1128-1135.	3.4	26
60	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4647-4659.	7.0	130
61	The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. <i>Annals of Oncology</i> , 2013, 24, 1130-1132.	1.2	17
62	The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. <i>Oncotarget</i> , 2013, 4, 1572-1581.	1.8	23
63	Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 160-71.	2.8	11
64	Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience. <i>Lung Cancer</i> , 2011, 73, 351-355.	2.0	12
65	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. <i>Drugs</i> , 2011, 71, 2231-2246.	10.9	23
66	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. <i>Blood</i> , 2011, 117, 7053-7062.	1.4	199
67	Notch3 signalling promotes tumour growth in colorectal cancer. <i>Journal of Pathology</i> , 2011, 224, 448-460.	4.5	77
68	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2011, 12, 922-933.	2.1	25